Contact
searchSearch
HMP Global

PSORIATIC ARTHRITIS

Joseph Merola
Conference Coverage
Joseph Merola, MD, MMSc, on the Long-Term Efficacy of Risankizumab for PsA
07/19/2023
Dr Merola and colleagues conducted a post hoc analysis of the KEEPsAkE 1 and 2 trials of risankizumab among patients with active psoriatic arthritis to evaluates patient subgroups at 52 weeks of treatment.
Dr Merola and colleagues conducted a post hoc analysis of the KEEPsAkE 1 and 2 trials of risankizumab among patients with active psoriatic arthritis to evaluates patient subgroups at 52 weeks of treatment.
Dr Merola and colleagues...
07/19/2023
Rheumatology & Arthritis
Joseph Merola
Conference Coverage
Joseph Merola, MD, MMSc, on the Long-Term Efficacy of Risankizumab for PsA
07/19/2023
Dr Merola and colleagues conducted a post hoc analysis of the KEEPsAkE 1 and 2 trials of risankizumab among patients with active psoriatic arthritis to evaluates patient subgroups at 52 weeks of treatment.
Dr Merola and colleagues conducted a post hoc analysis of the KEEPsAkE 1 and 2 trials of risankizumab among patients with active psoriatic arthritis to evaluates patient subgroups at 52 weeks of treatment.
Dr Merola and colleagues...
07/19/2023
Rheumatology & Arthritis
Alexis Ogdie
Conference Coverage
Alexis Ogdie, MD, on Clinical Measures and PROs in PsA
03/17/2023
Dr Ogdie, from the University of Pennsylvania, discusses the analysis of results from the KEEPsAKE trials of risankizumab regarding the association of clinical measures and patient-reported outcomes in psoriatic arthritis.
Dr Ogdie, from the University of Pennsylvania, discusses the analysis of results from the KEEPsAKE trials of risankizumab regarding the association of clinical measures and patient-reported outcomes in psoriatic arthritis.
Dr Ogdie, from the University of...
03/17/2023
Rheumatology & Arthritis
Alexis Ogdie
Conference Coverage
Alexis Ogdie, MD, on Clinical Measures and PROs in PsA
03/17/2023
Dr Ogdie, from the University of Pennsylvania, discusses the analysis of results from the KEEPsAKE trials of risankizumab regarding the association of clinical measures and patient-reported outcomes in psoriatic arthritis.
Dr Ogdie, from the University of Pennsylvania, discusses the analysis of results from the KEEPsAKE trials of risankizumab regarding the association of clinical measures and patient-reported outcomes in psoriatic arthritis.
Dr Ogdie, from the University of...
03/17/2023
Rheumatology & Arthritis
Laura Coates
Conference Coverage
Laura Coates, MBBS, on Upadacitinib Vs Adalimumab on RAPID3 Among Patients With Psoriatic Arthritis
02/22/2023
Dr Coates presented a poster at ACR Convergence examining the efficacy of upadacitinib vs adalimumab in treating psoriatic arthritis, using the RAPID3 tool to assess disease activity.
Dr Coates presented a poster at ACR Convergence examining the efficacy of upadacitinib vs adalimumab in treating psoriatic arthritis, using the RAPID3 tool to assess disease activity.
Dr Coates presented a poster at...
02/22/2023
Rheumatology & Arthritis
Laura Coates
Conference Coverage
Laura Coates, MBBS, on Upadacitinib Vs Adalimumab on RAPID3 Among Patients With Psoriatic Arthritis
02/22/2023
Dr Coates presented a poster at ACR Convergence examining the efficacy of upadacitinib vs adalimumab in treating psoriatic arthritis, using the RAPID3 tool to assess disease activity.
Dr Coates presented a poster at ACR Convergence examining the efficacy of upadacitinib vs adalimumab in treating psoriatic arthritis, using the RAPID3 tool to assess disease activity.
Dr Coates presented a poster at...
02/22/2023
Rheumatology & Arthritis
Alexis Ogdie, MD
Conference Coverage
Alexis Ogdie, MD, on PEST Screening Among Patients With PsO
02/13/2023
Rebecca Mashaw
Dr Ogdie, from the University of Pennsylvania, presented an abstract at ACR Convergence 2022 on research she and colleagues conducted highlighting the need to actively screen patients with psoriasis for their risk of developing psoriatic...
Dr Ogdie, from the University of Pennsylvania, presented an abstract at ACR Convergence 2022 on research she and colleagues conducted highlighting the need to actively screen patients with psoriasis for their risk of developing psoriatic...
Dr Ogdie, from the University of...
02/13/2023
Rheumatology & Arthritis
Alexis Ogdie, MD
Conference Coverage
Alexis Ogdie, MD, on PEST Screening Among Patients With PsO
02/13/2023
Rebecca Mashaw
Dr Ogdie, from the University of Pennsylvania, presented an abstract at ACR Convergence 2022 on research she and colleagues conducted highlighting the need to actively screen patients with psoriasis for their risk of developing psoriatic...
Dr Ogdie, from the University of Pennsylvania, presented an abstract at ACR Convergence 2022 on research she and colleagues conducted highlighting the need to actively screen patients with psoriasis for their risk of developing psoriatic...
Dr Ogdie, from the University of...
02/13/2023
Rheumatology & Arthritis
Alexis Ogdie
Conference Coverage
Alexis Ogdie, MD, on Response Rates in PsA: Results from the KEEPsAKE Trials of Risankizumab
11/14/2022
Dr Ogdie, from the University of Pennsylvania, reviews her poster presentation from ACR Convergence 2022 on response rates among patients treated with risankizumab based on the number of swollen and tender joints, from the KEEPsAKE 1 and 2...
Dr Ogdie, from the University of Pennsylvania, reviews her poster presentation from ACR Convergence 2022 on response rates among patients treated with risankizumab based on the number of swollen and tender joints, from the KEEPsAKE 1 and 2...
Dr Ogdie, from the University of...
11/14/2022
Rheumatology & Arthritis
Alexis Ogdie
Conference Coverage
Alexis Ogdie, MD, on Response Rates in PsA: Results from the KEEPsAKE Trials of Risankizumab
11/14/2022
Dr Ogdie, from the University of Pennsylvania, reviews her poster presentation from ACR Convergence 2022 on response rates among patients treated with risankizumab based on the number of swollen and tender joints, from the KEEPsAKE 1 and 2...
Dr Ogdie, from the University of Pennsylvania, reviews her poster presentation from ACR Convergence 2022 on response rates among patients treated with risankizumab based on the number of swollen and tender joints, from the KEEPsAKE 1 and 2...
Dr Ogdie, from the University of...
11/14/2022
Rheumatology & Arthritis

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use